<DOC>
	<DOCNO>NCT00434226</DOCNO>
	<brief_summary>This Phase II , randomize , control , open-label , multicenter trial design provide preliminary assessment safety efficacy sunitinib combine carboplatin paclitaxel chemotherapy bevacizumab patient locally advance , recurrent metastatic NSCLC receive prior systemic therapy NSCLC . All patient advance , histologically cytologically confirm NSCLC ( Stage IIIb pleural effusion , Stage IV , recurrent ) .</brief_summary>
	<brief_title>A Study Sunitinib Combination With Bevacizumab , Carboplatin , Paclitaxel Patients With Advanced Non-Small Cell Lung Cancer ( SABRE-L )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Signed Informed Consent Form Age ≥ 18 year Advanced histologically cytologically confirm NSCLC ( Stage IIIb malignant pleural pericardial effusion , Stage IV , recurrent ) Measurable nonmeasurable disease Patients treat brain metastasis eligible evidence progression hemorrhage treatment , ascertain clinical examination brain imaging ( MRI CT ) screen period ( brain imaging compete Day 7 Day 1 ) . Prior treatment CNS disease deem appropriate treating physician ECOG performance status 0 1 Ability willingness comply study followup procedure Prior systemic chemotherapy metastatic disease Active malignancy lung cancer Current , recent , planned participation another experimental drug study Prior treatment antiVEGF agent agent target similar pathway sunitinib Adjuvant chemotherapy prior combine modality neoadjuvant therapy ( chemotherapy plus radiotherapy without surgery ) within 6 month prior Day 1 Cycle 1 Life expectancy &lt; 12 week Current , recent , planned participation experimental drug study Inability take oral medication requirement IV alimentation total parenteral nutrition , prior surgical procedure affect absorption Inadequate organ function Known evidence disseminate intravascular coagulopathy Active infection fever &gt; 38.5°C within 3 day prior Day 1 Cycle 1 Untreated abnormal thyroid function test define institutional standard ( patient control hypothyroidism eligible study participation ) Any medical condition ( ) ( include mental illness substance abuse ) deem clinician likely interfere patient 's ability provide inform consent , cooperate , participate study , interfere interpretation result Intrathoracic lung carcinoma squamous cell histology Known CNS disease except treated brain metastasis Inadequately control hypertension Prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Class II great CHF History myocardial infarction unstable angina within 12 month prior Day 1 Cycle 1 History stroke transient ischemic attack within 12 month prior Day 1 Cycle 1 Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) recent peripheral arterial thrombosis within 6 month prior Day 1 Cycle 1 History hemoptysis within 1 month prior Day 1 Cycle 1 Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 Cycle 1 anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior Day 1 Cycle 1 History abdominal fistula gastrointestinal perforation within 6 month prior Day 1 Cycle 1 Serious , nonhealing wound , active ulcer , untreated bone fracture Proteinuria screening , demonstrate urine protein/creatinine ratio ≥ 1.0 screen Known hypersensitivity component bevacizumab sunitinib Pregnancy ( positive pregnancy test ) lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>SABER-L</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Avastin</keyword>
	<keyword>Sutent</keyword>
</DOC>